No photo of Antoinette Moran
Contact Expert

View Scopus Profile

Antoinette Moran

1989 …2022
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 30 Similar Profiles
Cystic Fibrosis Medicine & Life Sciences
Type 1 Diabetes Mellitus Medicine & Life Sciences
Insulin Resistance Medicine & Life Sciences
Insulin Medicine & Life Sciences
Glucose Medicine & Life Sciences
Pancreatectomy Medicine & Life Sciences
Fasting Medicine & Life Sciences
C-Peptide Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1995 2022

A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses ofAG019 administered alone or in association with teplizumab in subjects with clinical recent-onset Type 1Diabetes Mellitus (T1D).

Moran, A.

Intrexon Corporation

7/1/18 → 7/31/22

Project: Research project

Type 1 Diabetes Mellitus
Safety
teplizumab

TYPE 1 DIABETES EXTENSION STUDY (TIDES)

Moran, A.

BENAROYA RESEARCH INST AT VIRGINIA MASON

2/1/17 → 1/31/20

Project: Research project

EnVision CF: Emerging Leaders in CF Endocrinology

Moran, A.

Cystic Fibrosis Foundation

9/1/16 → 8/31/19

Project: Research project

Endocrinology

A Prospective Randomized Placebo-Controlled Double Blind

Moran, A.

Caladrius Biosciences Inc

6/1/16 → 3/30/20

Project: Research project

Regulatory T-Lymphocytes
Placebos
Clinical Trials
Safety

Impact of Insulin Therapy on Protein Turnover in Non-Dia

Moran, A. & Zhang, L.

Cystic Fibrosis Foundation

4/1/16 → 3/31/21

Project: Research project

Insulin
Proteins
Therapeutics

Research Output 1989 2019

Low-dose anti-thymocyte globulin preserves C-peptide, reduces HbA1c, and increases regulatory to conventional T-cell ratios in new-onset type 1 diabetes: Two-year clinical trial data

Type 1 Diabetes TrialNet ATG-GCSF Study Group, Jun 1 2019, In : Diabetes. 68, 6, p. 1267-1276 10 p.

Research output: Contribution to journal › Article

Open Access
Antilymphocyte Serum
C-Peptide
Type 1 Diabetes Mellitus
Clinical Trials
T-Lymphocytes
1 Citation (Scopus)

A novel triple-tracer approach to assess postprandial protein turnover

Moran, A., Toffolo, G., Schiavon, M., Vella, A., Klaus, K., Cobelli, C. & Nair, K. S., Oct 1 2018, In : American Journal of Physiology - Endocrinology and Metabolism. 315, 4, p. E469-E477

Research output: Contribution to journal › Article

Phenylalanine
Proteins
Meals
Blood Proteins
Proteome

A picture-based carbohydrate-counting resource for somalis

Sunni, M., Brunzell, C., Kyllo, J., Purcell, L., Plager, P. & Moran, A., Jan 1 2018, In : Journal of International Medical Research. 46, 1, p. 219-224 6 p.

Research output: Contribution to journal › Article

Carbohydrates
Medical problems
Food
Nutrition
Type 1 Diabetes Mellitus

Caregiving for children with type 1 diabetes and clinical outcomes in central India: The IDREAM study

Friedemann-Sanchez, G., Capistrant, B. D., Ron, J., Novak, L., Zuijdwijk, C., Ogle, G. D., Anderson, B., Moran, A. & Pendsey, S., May 1 2018, In : Pediatric Diabetes. 19, 3, p. 527-533 7 p.

Research output: Contribution to journal › Article

Type 1 Diabetes Mellitus
India
Caregivers
Hemoglobins
Child Care
2 Citations (Scopus)

Cystic-fibrosis-related diabetes: time for oral drugs?

Moran, A., Feb 1 2018, In : The Lancet Diabetes and Endocrinology. 6, 2, p. 85-87 3 p.

Research output: Contribution to journal › Comment/debate

Cystic Fibrosis
Diabetes Mellitus
Pharmaceutical Preparations